July 9, 2021 Information on the change in the shareholder structure due to execution of the Stock Grant Program in the Company – Art. 69 of the Act on Offerings
Read More
July 8, 2021 Correction of the current report No. 22/2021 of July 8, 2021
Read More
July 8, 2021 Conclusion of the share donation agreement between the Company and President of the Management Board and main shareholder of the Company in execution of a non-diluting incentive program in the Company
Read More
June 30, 2021 Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June, 29 2021
Read More
June 30, 2021 Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 11, 2021 Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)
Read More
June 2, 2021 Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
May 28, 2021 Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
Read More
May 20, 2021 Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021
Read More
May 17, 2021 Shareholders controlling at least 5% of the vote at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on May 17, 2021
Read More
May 17, 2021 Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
May 13, 2021 Information concerning impact of non-diluting incentive program on Company’s financial statements
Read More
May 12, 2021 New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Congress 2021
Read More
May 12, 2021 Ryvu Therapeutics S.A. Q1 2021 Financial Report
Read More
April 20, 2021 Declaration of establishing a non-diluting incentive program in the Company for the years 2021-2024
Read More
April 8, 2021 Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) by the FDA in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read More
April 8, 2021 Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
March 18, 2021 Conclusion of the grant agreement with the National Center for Research and Development
Read More
March 16, 2021 Ryvu Therapeutics S.A. Annual Report 2020
Read More
March 11, 2021 Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting
Read More
Posts navigation
